



## COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

## RECENT NEWS

### **Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results**

Nov 13 2025, 8:45 AM EST

### **Xenetic Biosciences, Inc. Announces Pricing of \$4.5 Million Underwritten Offering of Common Stock**

Oct 10 2025, 9:30 AM EDT

## STOCK OVERVIEW

|               |                  |
|---------------|------------------|
| Symbol        | XBIO             |
| Exchange      | Nasdaq           |
| Market Cap    | 5.89m            |
| Last Price    | \$2.57           |
| 52-Week Range | \$2.20 - \$13.93 |

11/13/2025 09:00 PM EST

## INVESTOR RELATIONS

JTC Team, LLC.  
Jenene Thomas  
T: 908-824-0775  
[xbio@jtcir.com](mailto:xbio@jtcir.com)

## MANAGEMENT TEAM

### **James F. Parslow**

Interim Chief Executive Officer and Chief Financial Officer

### **Scott N. Cullison**

Business Development

### **Reid P. Bissonnette, Ph.D.**

Translational Research and Development

## XENETIC BIOSCIENCES, INC.

945 Concord Street  
Framingham, MA 01701  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.